Cargando…
Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma
BACKGROUND: Bone lytic lesion in Multiple myeloma are the most commonly presented symptoms which require treatment with bisphosphonates (BPs). BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration ha...
Autores principales: | Krstevska, Svetlana, Stavric, Sonja Genadieva, Cevrevska, Lidija, Georgjievski, Borce, Karanfilski, Oliver, Sotirova, Tatjana, Balkanov, Trajan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AVICENA, d.o.o., Sarajevo
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720463/ https://www.ncbi.nlm.nih.gov/pubmed/26843726 http://dx.doi.org/10.5455/medarh.2015.69.367-370 |
Ejemplares similares
-
Tretatment Approach of Nontransplant Patients with Multiple Myeloma
por: Krstevska, Svetlana B., et al.
Publicado: (2014) -
Hairy Cell Leukemia Treatment: Where We Are Now?
por: Krstevska, Svetlana, et al.
Publicado: (2011) -
Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014) -
Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014) -
Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients
por: Walter, Christian, et al.
Publicado: (2010)